George Fennell Form 3 IDEXX LABORATORIES / GEORGE FENNELL ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

FENNELL GEORGE

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2024

3. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP, Chief Revenue Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,100	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Unit	⁽¹⁾	⁽¹⁾	Common Stock	108	⁽¹⁾	D
Restricted Stock Unit	⁽²⁾	⁽²⁾	Common Stock	97	⁽²⁾	D
Restricted Stock Unit	⁽³⁾	⁽³⁾	Common Stock	103	⁽³⁾	D
Restricted Stock Unit	⁽⁴⁾	⁽⁴⁾	Common Stock	167	⁽⁴⁾	D
Restricted Stock Unit	⁽⁵⁾	⁽⁵⁾	Common Stock	225	⁽⁵⁾	D
Restricted Stock Unit	⁽⁶⁾	⁽⁶⁾	Common Stock	639	⁽⁶⁾	D
Incentive Stock Option (right-to-buy)	⁽⁷⁾	02/13/2024	Common Stock	1,612	62	D
Non-Qualified Stock Option (right-to-buy)	⁽⁸⁾	02/13/2024	Common Stock	8,198	62	D
Incentive Stock Option (right-to-buy)	⁽⁹⁾	02/13/2025	Common Stock	1,256	79.54	D
Non-Qualified Stock Option (right-to-buy)	⁽¹⁰⁾	02/13/2025	Common Stock	9,986	79.54	D
Incentive Stock Option (right-to-buy)	⁽¹¹⁾	02/13/2026	Common Stock	1,476	67.85	D
Non-Qualified Stock Option (right-to-buy)	⁽¹²⁾	02/13/2026	Common Stock	11,345	67.85	D
Non-Qualified Stock Option (right-to-buy)	⁽¹³⁾	02/13/2027	Common Stock	5,302	141.6	D
Incentive Stock Option (right-to-buy)	⁽¹⁴⁾	02/13/2027	Common Stock	706	141.6	D
Non-Qualified Stock Option (right-to-buy)	⁽¹⁵⁾	02/13/2028	Common Stock	4,437	178.26	D
Incentive Stock Option (right-to-buy)	⁽¹⁶⁾	02/13/2028	Common Stock	560	178.26	D
Non-Qualified Stock Option (right-to-buy)	⁽¹⁷⁾	02/13/2029	Common Stock	4,826	206.94	D
Incentive Stock Option (right-to-buy)	⁽¹⁸⁾	02/13/2029	Common Stock	483	206.94	D
Non-Qualified Stock Option (right-to-buy)	⁽¹⁹⁾	02/13/2030	Common Stock	4,008	299.78	D
Non-Qualified Stock Option (right-to-buy)	⁽²⁰⁾	02/13/2031	Common Stock	1,805	544.08	D
Incentive Stock Option (right-to-buy)	⁽²¹⁾	02/13/2031	Common Stock	183	544.08	D
Non-Qualified Stock Option (right-to-buy)	⁽²²⁾	02/13/2032	Common Stock	1,768	505.53	D
Incentive Stock Option (right-to-buy)	⁽²³⁾	02/13/2032	Common Stock	197	505.53	D
Non-Qualified Stock Option (right-to-buy)	⁽²⁴⁾	02/13/2033	Common Stock	1,454	497.43	D
Incentive Stock Option (right-to-buy)	⁽²⁵⁾	02/13/2033	Common Stock	201	497.43	D

Explanation of Responses:

1. Grant of 544 restricted stock units ('RSU'). Each RSU represents a contingent right to receive one share of Issuer common stock and vest in five equal annual installments beginning on February 14, 2020.

2. Grant of 390 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four equal annual installments beginning on February 14, 2021.

3. Grant of 207 RSUs. Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four equal annual installments beginning on February 14, 2022.

4. Grant of 223 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning ion February 14, 2023.

5. Grant of 226 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four equal annual installments beginning on February 14, 2024.

6. Grant of 639 RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in one installment on June 1, 2026.

7. Grant of option to buy 806 shares of Issuer common stock that vested in one installment on February 14, 2019, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the Stock Split). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

8. Grant of option to buy 8,198 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

9. Grant of option to buy 628 shares of Issuer common stock that vested in one installment on February 14, 2020, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

10. Grant of option to buy 9,986 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

11. Grant of option to buy 1,476 shares of Issuer common stock that vested on February 14, 2021.

12. Grant of option to buy 11,345 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2017.

13. Grant of option to buy 5,302 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018.

14. Grant of option to buy 706 shares of Issuer common stock that vested in one installment on February 14, 2022.

15. Grant of option to buy 4,437 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2019.

16. Grant of option to buy 560 shares of Issuer common stock that vested in one installment on February 14, 2023.

17. Grant of option to buy 4,826 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2020.

18. Grant of option to buy 483 shares of Issuer common stock that vests in one installment on February 14, 2024.

19. Grant of option to buy 4,008 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2021.

20. Grant of option to buy 1,805 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2022.

21. Grant of option to buy 183 shares of Issuer common stock that vests in one installment on February 14, 2025.

22. Grant of option to buy 1,768 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2023.

23. Grant of option to buy 197 shares of Issuer common stock that vests in one installment on February 14, 2026.

24. Grant of option to buy 1,454 shares of Issuer common stock that vests in four annual installments beginning on February 14, 2024.

25. Grant of option to buy 201 shares of Issuer common stock that vests in one installment on February 14, 2027.

Remarks:

	/s/ George Fennell	01/05/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

George Fennell Form 3IDEXX LABORATORIES / GEORGE FENNELL ownership change